双鹭药业(002038) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥168,896,131.59, a decrease of 31.10% compared to ¥245,116,238.48 in the same period last year[5] - Net profit attributable to shareholders was ¥45,968,405.62, down 34.46% from ¥70,134,618.06 year-on-year[5] - The basic earnings per share decreased by 42.86% to ¥0.04 from ¥0.07 in the same period last year[5] - The company reported a significant decline in net profit excluding non-recurring gains and losses, which was ¥21,141,816.50, down 79.19% from ¥101,583,927.04 in the previous year[5] - The company's net profit for the current period is CNY 45,617,183.33, a decrease of 34.5% compared to CNY 69,675,806.49 in the previous period[20] - Operating profit for the current period is CNY 48,346,156.71, down 32.0% from CNY 71,156,814.33 in the previous period[20] - The company reported a net profit margin decline due to increased operating costs, impacting overall profitability[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥55,992,394.20, a decline of 152.45% compared to ¥106,747,075.24 in the previous year[5] - The company reported a net cash outflow from operating activities of CNY -55,992,394.20, compared to a net inflow of CNY 106,747,075.24 in the previous period[23] - Investment activities resulted in a net cash outflow of CNY -131,848,452.89, compared to CNY -24,793,699.08 in the previous period[23] - The company's cash and cash equivalents at the end of the period decreased to CNY 212,037,406.38 from CNY 621,996,815.09 at the end of the previous period[23] - Cash and cash equivalents decreased to ¥328,747,917.07 from ¥411,958,243.66, representing a decline of 20.1%[14] Operating Costs and Expenses - Total operating costs increased to ¥155,955,363.45, up 14.2% from ¥136,620,657.72 in the previous period[18] - The company incurred total sales expenses of CNY 19,904,477.41, an increase of 16.9% from CNY 17,035,038.54 in the previous period[20] - Research and development expenses increased slightly to CNY 28,942,931.49 from CNY 28,053,862.46 in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,064,702,839.06, reflecting a 1.43% increase from ¥5,979,019,318.74 at the end of the previous year[5] - Total assets increased to ¥6,064,702,839.06 from ¥5,979,019,318.74, reflecting a growth of 1.4%[16] - Total liabilities rose to ¥438,437,416.35, an increase of 10.1% from ¥398,371,079.36[16] - The equity attributable to shareholders increased by 0.82% to ¥5,618,416,348.02 from ¥5,572,447,942.40 at the end of the previous year[5] - Shareholders' equity increased to ¥5,626,265,422.71 from ¥5,580,648,239.38, a growth of 0.8%[16] Fair Value and Financial Changes - The company's financial expenses increased by 44.14% year-on-year, primarily due to reduced interest income from lower interest rates[9] - The fair value changes in financial assets increased by 157.94%, attributed to the market value fluctuations of holdings in Shouyao Holdings and Xinghao Pharmaceutical[9] - The company reported a significant fair value change gain of CNY 25,524,228.94, compared to a loss of CNY -44,049,648.74 in the previous period[20] Future Outlook - Future outlook includes potential market expansion and new product development strategies to enhance revenue streams[18]